What's Changed With Abbott Labs?

Abbott Labs' (NYS: ABT) upcoming spinoff company, AbbVie, is forefront on investors' minds at the moment, as it means the core company will lose its blockbuster drug Humira over to AbbVie. In this video, however, Motley Fool health-care analyst Brenton Flynn highlights some other preparations Abbott Labs is making ahead of the split, uncovered from the company's recent SEC filings, that show how Abbott may be streamlining the core business in a play to increase margins down the road.

The impending spinoff of Abbott's branded-drug business is a confusing event to understand, with many investors left wondering what to do with the two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand-new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.

The article What's Changed With Abbott Labs? originally appeared on Fool.com.

Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.